Logo image of ALAB

ASTERA LABS INC (ALAB) Stock Fundamental Analysis

NASDAQ:ALAB - Nasdaq - US04626A1034 - Common Stock - Currency: USD

107.66  +1.09 (+1.02%)

Fundamental Rating

4

Taking everything into account, ALAB scores 4 out of 10 in our fundamental rating. ALAB was compared to 108 industry peers in the Semiconductors & Semiconductor Equipment industry. No worries on liquidiy or solvency for ALAB as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, ALAB is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

ALAB had negative earnings in the past year.
ALAB Yearly Net Income VS EBIT VS OCF VS FCFALAB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2022 2023 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -2.67%, ALAB is doing worse than 61.11% of the companies in the same industry.
ALAB has a Return On Equity of -2.95%. This is in the lower half of the industry: ALAB underperforms 61.11% of its industry peers.
Industry RankSector Rank
ROA -2.67%
ROE -2.95%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALAB Yearly ROA, ROE, ROICALAB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2022 2023 -10 -20 -30

1.3 Margins

The Gross Margin of ALAB (68.94%) is better than 92.59% of its industry peers.
ALAB does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 68.94%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALAB Yearly Profit, Operating, Gross MarginsALAB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2022 2023 0 50 -50

More info and screens

9

2. Health

2.1 Basic Checks

ALAB does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALAB has about the same amout of shares outstanding than it did 1 year ago.
There is no outstanding debt for ALAB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ALAB Yearly Shares OutstandingALAB Yearly Shares OutstandingYearly Shares Outstanding 2022 2023 50M 100M 150M
ALAB Yearly Total Debt VS Total AssetsALAB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2022 2023 50M 100M 150M 200M

2.2 Solvency

ALAB has an Altman-Z score of 109.26. This indicates that ALAB is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 109.26, ALAB belongs to the best of the industry, outperforming 98.15% of the companies in the same industry.
ALAB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 109.26
ROIC/WACCN/A
WACC13.97%
ALAB Yearly LT Debt VS Equity VS FCFALAB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2022 2023 0 50M 100M 150M

2.3 Liquidity

ALAB has a Current Ratio of 10.74. This indicates that ALAB is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 10.74, ALAB belongs to the top of the industry, outperforming 97.22% of the companies in the same industry.
ALAB has a Quick Ratio of 10.46. This indicates that ALAB is financially healthy and has no problem in meeting its short term obligations.
With an excellent Quick ratio value of 10.46, ALAB belongs to the best of the industry, outperforming 98.15% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.74
Quick Ratio 10.46
ALAB Yearly Current Assets VS Current LiabilitesALAB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2022 2023 50M 100M 150M 200M

More info and screens

5

3. Growth

3.1 Past

ALAB shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 55.00%, which is quite impressive.
ALAB shows a strong growth in Revenue. In the last year, the Revenue has grown by 44.97%.
EPS 1Y (TTM)55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
Revenue 1Y (TTM)44.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, ALAB will show a very strong growth in Earnings Per Share. The EPS will grow by 77.08% on average per year.
ALAB is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 63.36% yearly.
EPS Next Y527%
EPS Next 2Y198.25%
EPS Next 3Y131.5%
EPS Next 5Y77.08%
Revenue Next Year235.35%
Revenue Next 2Y131.64%
Revenue Next 3Y96.66%
Revenue Next 5Y63.36%

3.3 Evolution

ALAB Yearly Revenue VS EstimatesALAB Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2022 2023 2024 2025 2026 2027 200M 400M 600M 800M
ALAB Yearly EPS VS EstimatesALAB Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 0.5 1 1.5

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALAB. In the last year negative earnings were reported.
Based on the Price/Forward Earnings ratio of 90.68, the valuation of ALAB can be described as expensive.
Based on the Price/Forward Earnings ratio, ALAB is valued a bit more expensive than the industry average as 61.11% of the companies are valued more cheaply.
ALAB's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 95.00.
Industry RankSector Rank
PE N/A
Fwd PE 90.68
ALAB Price Earnings VS Forward Price EarningsALAB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALAB Per share dataALAB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4 5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ALAB's earnings are expected to grow with 131.50% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y198.25%
EPS Next 3Y131.5%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALAB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ASTERA LABS INC

NASDAQ:ALAB (2/6/2025, 10:31:09 AM)

107.66

+1.09 (+1.02%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupSemiconductors & Semiconductor Equipment
GICS IndustrySemiconductors & Semiconductor Equipment
Earnings (Last)11-04 2024-11-04/amc
Earnings (Next)02-10 2025-02-10/amc
Inst Owners43.54%
Inst Owner Change3.06%
Ins Owners16.95%
Ins Owner Change-38.97%
Market Cap17.08B
Analysts84.44
Price Target120.63 (12.05%)
Short Float %6.11%
Short Ratio1.63
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)24.11%
Min EPS beat(2)15.86%
Max EPS beat(2)32.36%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)8.88%
Min Revenue beat(2)3.98%
Max Revenue beat(2)13.78%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)10.1%
PT rev (3m)57.9%
EPS NQ rev (1m)-0.32%
EPS NQ rev (3m)110.57%
EPS NY rev (1m)-0.26%
EPS NY rev (3m)24.85%
Revenue NQ rev (1m)-0.15%
Revenue NQ rev (3m)48.34%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)9.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 90.68
P/S 147.47
P/FCF N/A
P/OCF N/A
P/B 19.19
P/tB 19.19
EV/EBITDA N/A
EPS(TTM)-0.17
EYN/A
EPS(NY)1.19
Fwd EY1.1%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0.73
BVpS5.61
TBVpS5.61
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.67%
ROE -2.95%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 68.94%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.74
Quick Ratio 10.46
Altman-Z 109.26
F-ScoreN/A
WACC13.97%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)55%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%N/A
EPS Next Y527%
EPS Next 2Y198.25%
EPS Next 3Y131.5%
EPS Next 5Y77.08%
Revenue 1Y (TTM)44.97%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year235.35%
Revenue Next 2Y131.64%
Revenue Next 3Y96.66%
Revenue Next 5Y63.36%
EBIT growth 1Y51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year341.47%
EBIT Next 3Y140.27%
EBIT Next 5Y87.89%
FCF growth 1Y61.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y64.58%
OCF growth 3YN/A
OCF growth 5YN/A